Illumina (NASDAQ: ILMN) and Volcano Corp (NASDAQ:VOLC) are both large-cap advanced medical equipment & technology – nec companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, earnings, profitability, institutional ownership and analyst recommendations.
This table compares Illumina and Volcano Corp’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of current ratings for Illumina and Volcano Corp, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Illumina presently has a consensus target price of $199.28, suggesting a potential downside of 6.88%.
Institutional and Insider Ownership
93.0% of Illumina shares are owned by institutional investors. 1.6% of Illumina shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Earnings and Valuation
This table compares Illumina and Volcano Corp’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||NetIncome||Earnings Per Share||Price/Earnings Ratio|
|Illumina||$2.40 billion||13.03||$462.64 million||$5.30||40.38|
Illumina has higher revenue and earnings than Volcano Corp. Volcano Corp is trading at a lower price-to-earnings ratio than Illumina, indicating that it is currently the more affordable of the two stocks.
Illumina beats Volcano Corp on 8 of the 8 factors compared between the two stocks.
Illumina, Inc. (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc. (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations. Core Illumina’s products and services serve customers in the research, clinical and applied markets, and enable the adoption of a range of genomic solutions. The Company’s portfolio of integrated systems, consumables and analysis tools addresses the range of genomic complexity, price points, and throughput, enabling customers to select the solution for their research or clinical challenge. The Company provides reproductive-health solutions, including noninvasive prenatal testing (NIPT), preimplantation genetic screening and diagnosis, and neonatal and genetic health testing.
About Volcano Corp
Volcano Corporation designs, develops, manufactures and commercializes a suite of precision guided therapy tools including intravascular ultrasound (IVUS) and fractional flow reserve (FFR) products. The Company markets its products to physicians, nurses and technicians who perform endovascular based coronary and peripheral interventional procedures in hospitals and to other personnel who make purchasing decisions on behalf of hospitals. The Company’s products consist of consoles that are marketed as stand-alone units or as units that can be integrated into a variety of hospital-based interventional surgical suites called catheterization laboratories, or cath labs. The Company has developed customized cath lab versions of these consoles. The Company sells products directly to customers in the United States, Japan, certain European markets and South Africa. The Company’s products include consoles, IVUS products, FFR products, Pioneer plus re-entry catheter and crux VCF system.
What are top analysts saying about Illumina Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Illumina Inc. and related companies.